The advent of the isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, in glioma represents exciting progress for patients with IDH-mutant gliomas and neuro-oncology clinicians.1,2 An oral, targeted therapy represents a new model for neuro-oncology; many current treatments have finite cycles with expected end dates. This evidence concerns the gene IDH3A and glioma.